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ABSTRACT
Screening for and monitoring the progression of cancer remains a complex
task in medicine today, further complicated by the variety of both cancer
types and treatments. Each patient’s response to treatments and cancers is
unique, calling for a personalized approach to healthcare. Early detection and
correct treatment of cancer are critical for controlling disease progression and
improving patient outcomes.
This dissertation describes a photonic crystal-based detection and analysis
system to improve cancer screening and treatment by increasing sensitivity
to low concentrations of cancer biomarkers. There are two main methods of
increasing sensitivity: automating detection and analysis to reduce time and
user error, and improving coupling efficiency by optimizing photonic crystal
design parameters. I address both these methods in this work: the former by
increasing sensitivity in the screening for oropharyngeal cancer, and the latter
in the design of two new photonic crystals. The first of these photonic crystals
is designed for enhanced excitation of multi-colored quantum dots, instead
of traditional fluorescent dyes, for the investigation of multiplexed treatment
progression monitoring of prostate cancer. The second of these photonic crystals
is a design for metamaterial-based photonic crystals that improves coupling
efficiency and offers additional design flexibility. This new photonic crystal is
interchangeable with the photonic crystal designed to enhance quantum dots
but can also be used in a standard microscope setup. The objective is to retain
high enhancement while improving coupling to the photonic crystal resonance
to increase fluorescent output.
This work presents my efforts toward the development of technologies that
will enable low-cost, portable screening and disease monitoring to improve
outcomes for patients around the world. The ultimate goal is to improve patient
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Cancer screening is a critical part of medical practice today. It is generally
agreed that early diagnosis of cancer leads to better outcomes including re-
duction of side effects and improved life expectancy, as shown in Fig. 1.1
[1, 2]. Cancer is also more easily treated before the disease has metastasized
and a patient starts to show symptoms. Screening is especially important for
certain types of cancers, including breast, cervix, mouth, larynx, colon, rectum,
and skin [3]. However, reliable screening depends on an understanding of the
disease being screened for and an accepted treatment plan [4]. Cancer itself
is still not fully understood - with multiple disease pathways and individual
genetic mutations, it is difficult to accurately diagnose the cause of every cancer
and prescribe the correct treatment [3]. Once treatment has begun, it is also
important to monitor the disease progression to determine if the prescribed
drug therapy regimen is effective.
According to the 2014 World Cancer Report, there were 14.1 million new
cancer diagnoses worldwide and 8.2 million estimated cancer deaths in 2012
[3]. Cancer incidence increases with age as cells break down and acquire more
mutations. Regions of the world differ in which cancers are most common,
but the disease is a global problem without a universal cure. Some cancers,
like lung cancer, are frequently preventable, but others, like childhood cancer,
are unpredictable and often fatal without the correct intervention early in the
disease lifetime [3]. With the ubiquity of the disease, it is likely that even if
someone has not had cancer, she would know somebody affected.
Biosensors are a crucial part in the fight against cancer. These devices
convert changes in biology to detectable signals (light, in this case) [6]. My
research focuses on in vitro sensing using blood samples. These blood samples
contain biomarkers, which are targets of interest for disease and include cells,
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Fig. 1.1. Life expectancy and treatment timelines after cancer detection for
various scenarios: (A) “usual care,” (B) early detection, and (C) detection as
early as possible. Reproduced from Ref. [3], which was adapted from Ref. [5].
bacteria, viruses, proteins, hormones, enzymes, and nucleic acids [6]. Different
biomarkers are specific to screening or monitoring treatment of different cancers,
but they can typically be detected with a tag, such as a fluorophore [7], a
gold nanoparticle [8], a Raman dye [9], or simply detected by themselves in a
“label-free” environment [10]. Regardless of the detection method, there is a
critical need for biosensors with high specificity and sensitivity to accurately
screen or track cancer, especially in its early stages when cancer cells and
biomarkers exist in ultra-low concentrations [11].
Thus, cancer screening, diagnosis, and treatment depend on advancements
not only in cancer biology, but also in sensing methods to indicate the presence
or absence of biomarkers for cancer screening and treatment progression. My
research focuses on two types of cancer: oropharyngeal cancer (OPC) and
metastatic castrate-resistant prostate cancer (mCRPC). The ultimate goal is to
have a universal platform for disease monitoring and screening that can be easily
applied to indicators of different cancers and to treatment progressions. In
this work, I propose a photonic crystal (PC)-based solution for monitoring the
biomarkers for these cancers. Before expanding on my research, I will present
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an overview of PCs followed by exploring the advantages and disadvantages of
competing light-based biosensors.
1.2 Background
Before discussing the Cunningham group’s current generation of PCs, I will
give an overview of their predecessor, guided mode resonant filters (GMRFs).
Researchers proved that by either fabricating a grating of one dielectric material
on top of a separate dielectric material [12–14] or overcoating a dielectric
grating with another dielectric material [15], a resonance anomaly could be
achieved. These 1D, periodic structures were found to have resonance effects
due to the formation of a guided wave inside the layers. In this case, the
low-efficiency grating (h/λ << 1) couples light into the waveguide created by
the alternating refractive indices (RIs) of the dielectric layers [15]. Norton
describes these structures as having anomalies, where there is an overlap of the
“sharp” (resonance) and “broad” (Rayleigh) anomalies. The resonant grating
structures must contain a coupling mechanism (the grating), which excites
“leaky” modes in the waveguide [16]. For most purposes, it is sufficient to
account for only the zeroth (and possibly first) order modes.
In order for a resonance condition to occur, light inside the waveguide cavity
should undergo constructive interference. This is described by the Bragg
condition for a cavity depth d, average refractive index n, and an incident angle
φ:
2nd sinφ = mλ
where the phase accumulated during a round trip path across the cavity is
equal to an integer multiple m of the wavelength λ. Incident light not satisfying
this condition will destructively interfere and a standing wave can form.
In addition to the Bragg condition, there is also a momentum matching
condition to account for the effect of the grating periodicity on the wavelength
of incoming light. This is described by




Fig. 1.2. Comparison of
asymmetrical Fano (red) and
symmetrical Lorentzian (blue)
lineshapes. Reproduced from
Ref. [18] with permission from
The Royal Society of Chemistry.
where Λ is the grating period, β0 and φi correspond to the incident light, and




Note that there are two resonance conditions: the first being a Fabry-Perot
cavity with the Bragg condition and the second being a grating with momentum
matching [17]. The combination of these two resonances (grating and Fabry-
Perot) forms a Fano resonance [18] with the characteristic asymmetric lineshape
[19] as shown in Fig. 1.2. Proper design of the grating and the Fabry-Perot
cavity leads to a high-Q resonator, with the parameters of this resonance
tunable by the design parameters of the grating-coupled cavity.
A PC consists of a periodic variation of dielectric materials in either 1, 2, or
all 3 dimensions [20] with alternating high and low RI materials [21] (Fig. 1.3).
PCs were first named as such by Yablonovitch and Gmitter in 1989 when they
fabricated a 3D, face-centered-cubic array of Al2O3 spheres in dielectric foam,
experimentally demonstrating a “photonic band gap,” the electromagnetic
analog of an electronic band gap [22]. The simplest fabricated PC structure is
a type of GMRF, or 1D square grating. Such a structure is typically expanded
into 2D or 3D by etching holes or growing rods in a square, hexagonal, or even
more complex array. Confinement of light in a PC, the photonic band gap,
is due to a periodic RI variation, analogous to confinement of electrons, the
electronic band gap, which is due to the periodic atomic structure in a crystal
lattice [20]. Photonic band gap engineering is achieved by variations in material
RIs, thickness of materials, the periodicity, and even defects. Typically, 1D PCs
can confine light in only one direction, so 3D band gaps can only be achieved
with 3D PCs [20].
4
Fig. 1.3. Simple diagram of 1D, 2D, and 3D PCs in a square lattice.
Different colors depict materials with varying dielectric constants. Reproduced
from Ref. [20] with permission from Princeton University Press.
More information about PC fabrication and its use in my research can be
found in the following chapters of this work.
1.3 Competing Approaches
While there are numerous types of biosensors, including electrochemical, acous-
tic, and impedance, I will limit the analysis here to light-based biosensors.
These include ring resonators, waveguides/fibers, plasmonics, and Raman, as
well as newly discovered optical phenomena [23–25]. Optical biosensors have
the property of interacting with biological tags, such as fluorophores, that
are common detection mechanisms. They are also highly compatible with
traditional cleanroom fabrication techniques, meaning such devices can be easy
to design, fast, low-cost, and integrated in lab-on-a-chip technologies [26]. Like
the Cunningham group PCs, most of these approaches rely on the biomarkers
being within the evanescent field region, typically extending ∼100 nm from the
surface [27]. RI differences of the biomolecules change the coupling conditions,
and achieving the correct coupling conditions excites an evanescent field, which




Like all optical biosensors, waveguides are sensitive to RI changes on the sur-
face, making them good candidates for label-free detection [28]. There are two
main types of waveguides: cylindrical and planar [29]. Optical fibers are a
subset of cylindrical waveguides and are especially useful for remote sensing
and applications requiring flexible devices. There are more complicated config-
urations of waveguides for confinement of light in two dimensions, including
slot waveguides [30], rib waveguides [31], segmented waveguides [32], and strip
waveguides [33]. These types of waveguides add variation in a second dimension
in order to further control wave propagation.
In all cases, a high RI core is surrounded by a low RI cladding. Total internal








were n1 is the RI of the core and n2 is the RI of the cladding [34]. During TIR,
an external evanescent field extends outside the cladding into the surrounding
medium.
Despite their relative ease of fabrication, waveguides are not suitable for
large-area, general-purpose biosensors. Depending on their configuration, there
can be minimal extension of the evanescent field into surrounding medium,
reducing sensitivity. Waveguides also frequently require a prism coupler or
focusing optics in order to excite the resonant mode, increasing the device size
and complexity [29].
A unique type of waveguide, called a zero-mode waveguide, is highly applica-
ble for studying single-molecule processes at high concentrations [35]. These
waveguides, fabricated by etching small (r = 50 nm) holes in metal (Al), enable
the observation of real-time molecular activity, such as ligand binding events.
Metal-clad waveguides, in contrast to typical dielectric waveguides, have a
cutoff frequency below which no waves (or zero modes) will propagate [35]. At
these frequencies, the “zero-mode waveguide” will contain an evanescent field
inside the holes, exciting fluorescently labeled molecules.
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1.3.2 Ring Resonators
Ring resonators, also called whispering gallery mode (WGM) resonators, were
introduced as ultra-high sensitivity biosensors by Vollmer et al. in 2002 [36].
They have become especially popular for label-free, single nanoparticle detection
[37, 38]. Their operation is analogous to acoustic whispering galleries, such
as in St. Paul’s Cathedral in London [11]. In both cases, the wave travels
around the gallery in such a way that it constructively interferes with itself
at set intervals, based on TIR (Fig. 1.4). For optical biosensors, the resonant




where R is the radius of the ring, neff is the effective RI, and m is a positive in-
teger [18]. This is derived using the Bragg condition, except instead of traveling
round trip through a cavity, the wave travels in a complete circle. Architectures
for ring resonators include planar resonators, microspheres, microtoroids, and
liquid core optical ring resonators.
RI sensing in WGM resonators is based on detection of the shift in neff in
the medium surrounding the ring [18]. These RI changes lead to a shift in λres,











Like most label-free optical biosensors, a figure of merit is the resonance shift
per change in RI, with units nm/Refractive Index Unit (RIU).
The resonance of WGM sensors can also be used to enhance other optical
processes, including fluorescence and optical absorption, instead of detecting
change in RI [18]. In both cases, the evanescent field from the ring interacts
with the medium outside of the ring. This field can be used either to excite
the fluorophores for fluorescence measurements or as a probe for absorption
methods to estimate concentration [18].
While ring resonators are ideally suited for single-molecule detection, their
device complexity is not very suitable for large-area, general-purpose biosensors.
Large-scale fabrication of micro- and nano-sized rings becomes expensive, and
the ring resonators start to interfere with each other if placed too closely
together [18]. With nanoscale sensors, it also becomes difficult to guarantee co-
location of the rings and molecules of interest without complicated preparation
procedures.
1.3.3 Plasmonics
Unlike resonance effects in dielectrics caused by a change in RI, plasmon
resonance is caused by electron oscillation in metals [39, 40]. This effect can
result from either of two physical manifestations: surface plasmon resonance
(SPR) and localized surface plasmon resonance (LSPR) [41]. SPR is the
oscillation of electrons in a metal layer, while LSPR is oscillation of electrons
in metal nanoparticles (Fig. 1.5a-b) [40]. Both of these phenomena have their
advantages in biosensing.
The first use of SPR for label-free biosensing was by Englebienne in 1998 for
real-time monitoring of antigen-antibody binding on a colloidal gold surface
[42]. Like in waveguides and ring resonators, the resonance shift is due to a
change in RI near the surface of the biosensor. In the case of the SPR sensor,
a larger resonance shift implies that a larger mass has bound to the metal
surface, making it more difficult for electrons to oscillate, resulting in a lower
energy (red-shifted) resonance [42].
From SPR, researchers quickly moved to LSPR, as nanoparticles can much
more easily be tuned to a desired resonance by altering their size and shape




Fig. 1.5. Depictions of (a) a surface plasmon polariton (or propagating
plasmon) and (b) a localized surface plasmon. Reproduced from Ref. [40] with
permission from Annual Reviews.
first, the evanescent field travels too far into the neighboring dielectric layer,
sending energy farther than needed to detect biomolecules; second, coupling into
an SPR is difficult to achieve and usually requires a prism-coupler, increasing
size and complexity of the device; finally, SPR surface waves propagate in the
10 µm to 100 µm range, meaning sensing applications smaller than that are not
easily feasible [44].
The first LSPR device for biosensing was made by Haes and Van Duyne in
2005 for detection of a biomarker for Alzheimer’s disease [45]. Many biosen-
sors have been fabricated since, using advances in nanotechnology to expand
the scope of LSPR to plasmon-photon interactions [46], plasmonic nanorods
[43], single-nanoparticle sensing [39], and plasmonic nanoantennas [47]. The
enhancement of LSPR biosensors is naturally limited to the area around the
nanoparticles, but the advantages of easier coupling and customization out-
weigh the smaller electric field magnitudes [44]. However, LSPR devices still
present complications for biosensors, most notably the fact that metals are
lossy. This lost energy is converted to heat radiating from the nanoparticles,
which has the potential to compromise biological specimens [48–50].
1.3.4 Surface-Enhanced Raman Scattering
Surface-enhanced Raman scattering (SERS), like SPR and LSPR, depends on
plasmon oscillations in metals for resonant field effects [40]. Instead of detecting
RI changes or fluorescence, SERS enhances the detection of Raman spectra of
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biomarkers or their Raman dye tags. The Raman effect was first published in
1928 by C.V. Raman. He noticed that, under bright illumination, the spectra
of some liquids contained wavelengths not present in the illumination source
[51]. These spectral lines were vibrational modes of the measured liquids, with
different liquids having different Raman spectra. Instead of Rayleigh scattering,
where an excited molecule relaxes back to its original state, Raman scattered
molecules absorb some of the excitation energy into vibrational modes. Thus,
for Stokes Raman scattering, the scattered wavelength will be longer (lower
energy) than the excitation wave. While rarer, anti-Stokes Raman scattering
occurs when an molecule in an excited vibrational state relaxes back down to
the ground state. The amplitude of Raman spectral peaks is typically very
small (representing about 10−6 of incident photons) and needs enhancement
[52]. SERS, then, uses LSPR to enhance Raman spectra of molecules in the
near-field of the nanoparticles used to generate the LSPR.
Raman scattering, and SERS in general, were initially used for structural
and chemical analysis of molecules [52]. The first use of SERS for biosensing
was in 1977 by Jeanmaire and Van Duyne for studying molecules adsorbed
on the surface of silver electrodes [53]. Since that time, researchers have
combined SERS with lateral flow assays [54, 55], waveguides [56], and nanohole
arrays [57] to detect DNA, antibody-antigen binding events, and metal ions,
as an example. All of these methods seek to either integrate SERS into more
traditional biological sensing or to mitigate some of its disadvantages. Notably,
like LSPR, the peak enhancement of SERS only occurs in close proximity to
the nanoparticle, and metal nanoparticles are still subject to heating effects,
potentially compromising the biological specimens.
1.3.5 Dielectric Nanoantennas
Dielectric nanoantennas arose from the need to overcome the heat radiated from
typical metallic nanoparticles used for SERS and LSPR biosensing. Metallic
nanoparticles are lossy, and the loss radiates as heat [48–50]. It is always
desirable to minimize loss, but heat poses an additional problem for integra-
tion with biological specimens: the potential to damage the material under
investigation. In the past few years, many research groups have successfully
fabricated dielectric nanoantennas as simple arrays [58, 59] and dimers [48–50],
10
in contrast to the much wider array of shapes seen with metal nanoparticles
(bowties, flowers, rods, etc).
These research efforts into dielectric nanoantennas have very recently inspired
some research into nanoantenna biosensors. Both Yavas et al. and Bontempi
et al. have fabricated silicon nanodisk arrays to detect prostate-specific antigen
and biotin-streptavidin binding, respectively [58, 59]. They both show high
sensitivity and real-time detection, hopefully driving the effort to more fully
realize this new technology.
1.3.6 New Materials
In recent decades, new classes of biosensors have been reported that were
previously undiscovered or simply not fabricatable with the latest technology.
These materials, called metamaterials, were first fabricated in 1999, when
Pendry et al. created a magnetic structure from nonmagnetic conducting
sheets [60]. Metamaterials are engineered structures made of metal and/or
dielectric materials that have properties not traditionally found in nature
[61]. Such materials were theoretically predicted in Veselago’s landmark 1968
paper discussing negative permittivities and permeabilities and their potential
applications [62]. In theory, metamaterials can be used to fabricate perfect
lenses [63], cloaking devices [64], flat lenses [65], and photonic hypercrystals
[66], as well as used to generate a whole new class of surface waves called
Dyakonov waves [67], among numerous other phenomena, many likely yet to be
discovered. In reality, metamaterial performance is often limited by material
losses and bandwidth limits, but advances in research and nanotechnology are
closing these gaps.
There have been several recent publications of researchers using metamaterials
and new physical phenomena to do biosensing. Most recent work is in the
early stages: one paper demonstrates that Dyakonov waves can be used for
biosensing [68]; others report the detection of single nanoparticles [69], single
particles [70], or ultra-low concentrations of standard biomolecules [71]; and yet
another demonstrates the capability of metamaterials to sense RI changes using
simulations [72]. I expect that future research into metamaterial biosensors
will make them more widely applicable and easier to fabricate.
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1.4 Dissertation Structure
This dissertation is structured as follows:
• Chapter 2 describes a new software and analysis methodology for scan-
ning and analyzing PCs using fluorophore-based detection. This system
was used to image and analyze patient sample data for oropharyngeal
cancer, paving the way for an all-in-one, low-cost, high sensitivity, disease
screening system.
• Chapter 3 discusses a new PC and optical setup for enhancing excitation
of quantum-dot tagged biomarkers instead of fluorophores. Unlike flu-
orophores, different quantum dots are excited at the same wavelength,
so excitation of QDs with varying emission wavelengths can be used to
effectively multiplex biomarker detection.
• Chapter 4 introduces a PC utilizing hyperbolic metamaterials that is
compatible with the system developed in Chapter 3. This new device
expands coupling conditions to make PCs more compatible with standard
microscopes and other more portable optical setups.
• Chapter 5 includes a proposal for continuing the work of Chapter 3 by
using quantum dot-tagged messenger RNA as an marker of treatment





ANALYSIS OF AN ANTIVIRAL ANTIBODY
CANCER BIOMARKER IN SERUM
2.1 Introduction
We demonstrate the PCEF platform for detecting anti-E7 antibody, a biomarker
for human papillomavirus (HPV)-associated oropharyngeal cancer (OPC),
representing an application with a significant unmet clinical need that can
benefit from point-of-care analysis. HPV is commonly associated with various
cancers, and of the ∼200 different types of HPV, 15 are considered high-risk
[73]. Proteins produced early in the viral life cycle—specifically E6 and E7—are
known to play important roles in initiating and maintaining the malignant
transformation of host cells [73]. Forty to eighty percent of OPC cases have
been attributed to HPV, and of these, up to 90% are caused by HPV16 [74].
Importantly, 46− 50% and 63− 69% of OPC cases have been demonstrated
to be seropositive for HPV16 E6 and E7, respectively, with antibodies (IgG)
to either E6 or E7 detected in less than 4% of healthy controls [75–77]. The
identification of HPV association is clinically important, as the recommended
therapy will be partially determined by HPV exposure, and HPV-OPC patients
have a better prognosis than non-HPV-associated OPC patients [74].
Here, we focus on using the PCEF assay platform to detect anti-E7 IgG
antibodies in both spiked serum samples and clinical samples with unknown anti-
E7 antibody concentration to demonstrate the automation of PCEF detection
©2018 IEEE. Adapted, with permission, from C.M. Race et al., “An automated mi-
crofluidic assay for photonic crystal enhanced detection and analysis of an antiviral antibody





Fig. 2.1. (a) Schematic of the photonic crystal (PC) structure, composed of a
high refractive index (RI) TiO2 layer and low RI SiO2 layer on a silicon
substrate. (b) A 2 mm× 8 mm PC with some visible printed protein spots on
a penny for size comparison. (c) Photo of the PC-integrated single- (left) and
four-channel (right) cartridges, with food coloring to indicate sample flow
channel. Sample is introduced through the sample inlet holes, at the outside
edges of the PCs. In the four-channel cartridge, the center hole serves as the
common inlet for reagents once connected to the automated flow system.
and analysis. Our publication also considers this platform to demonstrate
its potential for use in clinical diagnostic applications, but that discussion is
beyond the scope of this work [78].
PCs are comprised of a periodically modulated surface of alternating high and
low refractive index (RI) materials (Fig. 2.1a). The PCs used in this work consist
of a low RI silicon dioxide (SiO2) sub-wavelength, one-dimensional grating
structure coated with a high RI titanium dioxide (TiO2) layer, as described
previously [79] and in the Methods section. With the correct combination of
incident wavelength and angle, the “on-resonance” condition is fulfilled and a
standing wave is generated within the TiO2 layer of the PC that extends, in
the form of an evanescent field, into the surrounding media (such as air) above
the PC surface. Satisfying the boundary conditions derived from Maxwell’s
equations, the evanescent field magnitude decays exponentially with increased
distance from the surface of the PC.
The resonant electromagnetic coupling between light and the PC structure is
the source of two enhancement mechanisms: enhanced excitation and enhanced
extraction. The optical mechanisms behind PC enhanced excitation and
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Fig. 2.2. Line scanner
schematic. Both the
laser diode and the
sample are on motorized






enhanced extraction have been thoroughly described previously [10]. Briefly, the
PC couples light from a collimated, monochromatic (laser) illumination source
for a narrow range of incident angles, at which an electromagnetic standing
wave is established in the TiO2 layer of the PC with a magnitude that greatly
exceeds the electric field intensity of the incident light. Through PC enhanced
excitation, fluorescent dye molecules on the PC surface are exposed to greater
electric field intensity than they would receive if they were on an ordinary glass
surface. While a similar effect could be achieved by utilizing a more powerful
laser, PC enhanced excitation achieves amplification of only surface-bound
fluorophores (thus reducing background fluorescence) and enables the use of an
inexpensive, low-power laser diode as the light source. PC enhanced extraction
occurs for any photon emitter with a wavelength that approximately matches
the wavelength of a resonant mode of the PC. While fluorescence emission on
a glass substrate ordinarily radiates in all directions, the enhanced extraction
effect directs emission normal to the PC surface, enabling the detection optics
to collect a greater proportion (5 − 10×) of all emitted photons. The PCs
used in this work, in conjunction with the laser scanning detection instrument,
take advantage of both effects. The combination of the two effects results in
PC enhanced fluorescence (PCEF), with enhancement up to 8000× at the PC
surface [7]. Importantly, the detection instrument [7, 80] (Fig. 2.2) incorporates
a motorized stage which enables tuning of the incident laser to its optimal
“on-resonance” angle, at which the greatest enhanced excitation effect occurs.
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Previous publications on the topic of PCEF for protein microarray appli-
cations have demonstrated the design and fabrication of silicon-based PCs
[7, 79, 81, 82], a laser-scanning detection instrument with manual on-resonance
adjustment [80], 3D-printed (via stereolithography) single-sample microflu-
idic cartridge and automated microfluidic control [82], and printed capture
antibodies. The goal of this chapter involves the implementation of several
modifications to make the technology platform compatible with a point-of-care
testing environment, in which we envision a desktop instrument with a cost
of less than $10K that could be utilized by trained technicians in a health
clinic. Ideally, the PCs must be embedded in a low-cost, easily manufacturable,
single-use disposable cartridge into which the user introduces a single droplet
of serum. The cartridge is inserted into an assay automation station containing
reservoirs of two reagents (wash buffer and fluorophore-labeled secondary anti-
body). Due to the length of time required for the incubation steps of the assay,
it is important to enable assays on independent test samples to be conducted
simultaneously. Thus, cartridges allowing for the multiplexed testing of samples
are desirable to facilitate these concurrent assays.
After the assay is complete (including automated drying of the PC surface),
the cartridges are inserted into the laser-scanning detection instrument. Ideally,
the user would have no interaction with the detection instrument other than
to insert the cartridge and to initiate a scan. Therefore, mechanical align-
ment of the microarray to the scanned field of view, adjustment of the laser
scanning instrument for optimal “on-resonance” illumination, determination
of fluorescent spot intensities, and checking of internal controls for a valid
test must all be performed automatically. The combined capabilities reported
here represent a substantial engineering improvement that advances PCEF
microarray technology from a labor-intensive laboratory capability toward a
point-of-care automated technology.
2.2 Methods
2.2.1 Photonic Crystal Fabrication
The design and fabrication of silicon-based PCs used in this work has been
described previously [7, 79]. Briefly, approximately 840 nm of low RI SiO2
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was deposited on an 8 in diameter Si wafer, followed by deep UV lithography
and reactive ion etching to fabricate a 40 nm-deep grating with a period of
360 nm and 36% duty cycle (Novati Technologies Inc.). Next, a 150 nm thick,
high RI TiO2 layer was applied to the wafer by sputter deposition (Intlvac
Inc.), resulting in the final device schematized in Fig. 2.1a. The wafer was
subsequently diced into 2 mm× 8 mm pieces (Fig. 2.1b) for incorporation
within the single-channel or four-channel microfluidic cartridges (Fig. 2.1c).
Fabrication upon 8 in diameter silicon wafers using tools and methods that
are conventional for integrated circuit manufacturing assures a high degree of
intra-PC uniformity and a high degree of reproducibility between independent
PCs within a wafer and between wafers. All PCs have a resonant wavelength
near 628 nm, with a bandwidth of ∼2 nm, and a resonant reflection efficiency of
∼ 80%. The devices are designed for utilization in air, and resonant reflection
spectra have been reported previously [7].
2.2.2 Line Scanner
Using the custom line scanning instrument (Fig. 2.2) [80], the first step of the
detection process is to scan the surface of the PC to capture images of the
fluorescently tagged protein spots (Fig. 2.3a). Importantly, the instrument is
able to precisely adjust the incident angle of the laser illumination via motor-
controlled linear translation of the distal end of the optical fiber that supplies
light to the PC. The focal point of the cylindrical lens is at the back focal plane
of the objective lens, so linear translation of the fiber tip results in modulation
of the angle of light incident on the PC surface. In the system, 500 µm linear
translation of the fiber end results in an approximately 1.59° modulation of
the angle of incidence, and the angle can be controlled with 0.025° accuracy.
The first step of the scanning process is to find the resonant angle of the PC
within the E7 spots. Due to the mass density of the proteins printed and
bound to the surface, the resonance angle of the PC is shifted by up to 2°
between the silanized PC surface and the areas containing fluorescently tagged
molecules, as shown in Fig. 2.4. To account for the additional resonance angle
shift after binding of the anti-E7 and secondary antibodies, it is critical to
measure the resonance angle of the E7 spots by scanning the angle from 0° to
8° to determine the angle at which maximum fluorescence intensity is emitted
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(a) (b)
Fig. 2.3. (a) (top) Bright-field microscope image of protein microarray, where
the red region corresponds to the area scanned with the line scanner, with the
vertical laser line moving in the direction of the red arrow. (middle)
Fluorescence intensity image obtained using the PCEF laser line scanner.
(bottom) Result of the automated spot-finding algorithm. (b) Schematic of
fluorescence-linked immunosorbent assay (FLISA). Figure courtesy of Lydia
Kwon.
from the E7 spots on the PC. Spots near the edge of the PC are used for this
on-resonance-angle-finding procedure so as not to photobleach the spots that
will be scanned for analysis and quantification.
After the on-resonance angle is recorded, the sample stage is translated
to an unscanned area of the chip to perform an on-resonance scan followed
by an off-resonance scan (at an incident angle of 8°). On- and off-resonance
scans are performed at the same location, across the length of the printed
spots on the PC surface, to estimate the enhancement factor for the enhanced
excitation mechanism. The pixel size of the CCD camera is approximately
1.6 µm× 1.6 µm, so images are gathered at 2 µm increments in the direction
perpendicular to the laser line. A sliding window algorithm is used to combine
the line-scanned images together to form a fluorescence intensity image of the
surface. For the sliding window algorithm, the fluorescence intensities of 5
consecutive scan lines are added together for each location on the surface. In
other words, although the pixel width in the scan direction is only 2 µm, the
computer captures a 10 µm image to get fluorescence information for 2 pixels
away from the center in either direction. This ensures that the result is the
best estimate of fluorescence output due to the Gaussian intensity distribution
of the laser intensity in the direction perpendicular to the scanning line.
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Fig. 2.4. Reflection spectrum of
PC coated with: epoxysilane
(blue), casein (green), and
anti-E7 (orange).
2.2.3 Apodization Filter
The line scanning system incorporates an apodization filter in the optical
path after the cylindrical lens, as shown in Fig. 2.2. The laser line has a
Gaussian profile as measured along the length of the scan line, which results
in non-uniform illumination of the fluorescent spots across the width of the
chip. Spots in the center of the line receive approximately 2× greater intensity
than spots displaced only 200 µm from the center. The consequence of this
non-uniform illumination is a large standard deviation of spot intensities of
replicate assay spots. An apodization filter partially attenuates the center of
the scan line, resulting in more uniform illumination and ensuring that the
fluorescence intensity at the line edge is similar to the fluorescence intensity at
the center (Fig. 2.5a). The apodization filter was fabricated by depositing a
thin layer (∼12 nm) of gold, 4 mm in diameter, at the center of an optically
transparent glass plate (Fig. 2.5b).
2.2.4 Automated Data Analysis
To perform data analysis on the fluorescence intensity images, I have imple-
mented an automated algorithm to find and analyze the spots with minimal
user input (Fig. 2.3a(bottom)). The algorithm uses Bernsen filtering and
watershedding to identify local differences in intensity and to separate any
unintended “satellite spots” (smaller, residue spots formed when more than one
droplet is expelled from the printer tip during protein microarray printing) from
the main printed protein spots [83]. Spots are also filtered by size and shape to
exclude non-elliptical objects and background artifacts. This algorithm takes
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(a) (b)
Fig. 2.5. (a) Comparison of laser line profile on bare PC before (orange) and
after (blue) integration of apodization filter. (b) Photo of apodization filter.
as input raw fluorescent intensity data and outputs spot statistics, including
spot median intensity, standard deviation, and average intensity of each column
of spots. Each column of spots represents the positive control, negative control,
experimental control, or biomarker.
After manual selection of a representative blank area of the PC for the back-
ground region, the algorithm subtracts the median intensity of the background
spot from the median intensity of the corresponding protein spot, thereby
accounting for vertical variations in the PC or in the laser line illumination.
This method provides minimum covariance between spots, compared to other
statistical analysis methods (e.g., excluding background subtraction, average
spot intensity, or maximum spot intensity) [84]. By averaging each background-
subtracted spot column, the algorithm computes enhanced excitation factor,
which is defined as the on-resonance intensity divided by the off-resonance
intensity of each assay column, providing insight into how accurately the
on-resonance angle has been determined.
2.3 Results and Discussion
To validate the new method of finding the on-resonance angle, semiconductor
quantum dots (QDs) from the Smith lab were used to quantify the output
intensity at incremental deviations from the optimal resonance angle. QDs
do not photobleach as quickly as organic fluorophores [85], enabling repeated
scanning of the PC with a relatively stable emitted light intensity between
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Fig. 2.6. Illustration of
QD-tagged spot intensities
(background subtracted) at
different angles of illumination
with respect to the resonance
angle. Note that both samples
exhibit highest intensity at the
resonance angle.
subsequent scans. Because the 637 nm wavelength laser in the scanning setup
is not optimal for typical QDs, the Smith lab provided alloyed (core)shell
(HgxCd1-xSe)CdyZn1-yS QDs [86] which exhibit enhanced excitation efficiency
in the red and detectable emission at 685 nm. The on-resonance angle was ob-
tained for different concentrations of the anti-E7 antibody and the fluorescence
intensity was measured at angles near the on-resonance angle (Fig. 2.6). The
background-subtracted QD intensity is always maximized at the on-resonance
angle, with the intensity decreasing as the incident angle deviates from the
resonance condition. While intensity is largest at the resonance condition, the
decay on either side is asymmetric. This discrepancy can be explained by the
order in which these scans at different angles were performed, as the QDs
gradually photobleach (significant decrease in intensity could not be detected
after 3 min of continuous illumination) [87]. The PCs were first scanned at the
on-resonance condition, followed by −0.2°, then 0.2°, then −0.4°, and finally
0.4° away from the on-resonance condition.
As described in the Methods section, an automated spot-finding and analysis
algorithm was implemented to reduce both data analysis time and user bias.
The most notable improvement was in the time spent on data analysis, which
improved up to 10-fold (approximately 30 min per chip) compared to finding
spots and calculating average intensities manually. Furthermore, this method
was used to thoroughly evaluate different analysis methods of calculating
spot intensities (such as average, median, or maximum, all with or without
background subtraction) that minimized covariance between different spots of
the same biomolecule. The algorithm ensures that all spots are analyzed in the
same manner and that comparison between different data sets is statistically
21
valid. Other groups have generated spot-finding algorithms [88], but this one is
specifically applicable for fluorescence assays because it includes distinguishing
main spots from satellite spots and accounts for non-uniformity in spot size,
location, and spacing on the PC surface.
To use the PCEF platform for detection of anti-E7, a biomarker for HPV-
associated OPC, we completed assays for a total of 40 clinical samples (gathered
from 20 OPC patients and 20 healthy controls) at both on- and off-resonance.
Conventional ELISAs were run concurrently on aliquots of the same samples by
the Demirci Lab (Stanford University) [89]. The goal was to evaluate the diag-
nostic capability of PCEF platform to provide positive/negative discrimination
of the presence of anti-E7 antibody, rather than to assess the clinical relevance
of the antigen-antibody interaction of protein E7 and anti-E7 antibody in
OPC patients. Therefore, the ELISA—an established diagnostic method—was
chosen as the gold standard reference.
Figure 2.7 shows the off- and on-resonance E7 spot images obtained with
PCEF, compared to the ELISA results and OPC status of select samples.
Samples 1 and 2 represent those samples in which both the off- and on-
resonance results correlated with both the ELISA and OPC status. Samples
3 through 9 represent samples in which there were discrepancies between the
quantitative PCEF results and the ELISA status. More specifically, samples
3 through 5 indicate instances where at least one PCEF result (off- or on-
resonance) was positive for an ELISA-negative sample. Meanwhile, samples
6 through 9 represent cases in which at least one PCEF result was negative
for an ELISA-positive sample. Sample 9 is the one case in which both PCEF
results were negative for an ELISA-positive sample.
While the assay did not compare perfectly to ELISA, there are promising
results. Most notably, the enhancement factor (on-resonance intensity vs. off-
resonance intensity) typically ranged from 10− 25×, with some enhancement
factors being as large as 200×. This means that the angle-finding method
worked well on a variety of samples with different densities. There were two
main issues: on-resonance spots being too bright for a “negative” result, and
high background noise such that visible spots are considered “negative.” Both
of these can be partially attributed to non-specific binding: the blocking
agent (to prevent non-specific binding) did not work as well as it could have,
potentially interfering with the data. These are improvements to be made
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Fig. 2.7. PCEF results at off-
and on-resonance, compared to
ELISA results and OPC status
for select samples, 1 through
9 , representing different
variations in agreement between
PCEF and ELISA results.
Figure courtesy of Lydia Kwon.
before performing the next assay. We can also improve the calculation of
background spot intensity for noisy assays in the data analysis software.
2.4 Conclusion
In this chapter, I have described methods for automating scanning and detection
of oropharyngeal biomarkers using photonic crystal enhanced fluorescence.
Data analysis time has significantly decreased without increasing errors made.
The line scanning and data analysis system were first applied here to protein
biomarkers for OPC. The accuracy in finding the “on-resonance” angle was
improved and a method for automatically detecting fluorescence spot location
on the PC surface, independent of location or brightness, was implemented.




A NEW SYSTEM FOR EXCITATION AND
DETECTION OF QUANTUM DOTS USING
PHOTONIC CRYSTALS
3.1 Introduction
Quantum dots (QDs) are becoming common alternatives to fluorophores in
labeling and detecting biomolecules for live cell imaging [90–92], assays [93–96],
and in vivo work [97–99]. The ability to design the size and composition of
QDs in order to vary emission wavelength and intensity properties is highly
desirable for these biological applications. Their resistance to photobleaching,
broad excitation spectra, and high quantum-yield also make them much more
efficient and easier to work with than traditional fluorescent dye molecules [92].
The Cunningham group has done previous work integrating QDs into 2D
photonic crystals (PCs) for enhancing laser excitation and quantum dot emission
[100–103]. The QDs embedded in these PCs undergo the Purcell effect, where
the spontaneous emission rate of the QD is enhanced when coupled to a
resonant cavity [104, 105]. The downside to this approach is that PCs have
to be designed for the emission wavelength of each QD used. This becomes
difficult for biological applications where multiplexing is desired or where QDs
cannot be precisely placed on the surface for maximum enhancement.
I introduce the design of PCs to instead enhance the QD excitation, which
is uniform for all emission wavelengths [86]. This approach will also enhance
the emission of the QDs with the advantage that multiplexed detection can
be performed with a combination of QD emission wavelengths and output
intensities [103]. The emission wavelength in the QDs is sufficiently far away
from the excitation wavelength (>100 nm) such that the absorption of the
PC will not inhibit the decay rate, as it does for slightly decoupled QDs
[104, 105]. In this work, I will detail the design and simulation of this new PC
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(a) (b)
Fig. 3.1. (a) Ideal 1D PC with parameters corresponding to those in
Table 3.1. n1 = nSi3N4 and n2 = nSiO2 . Not to scale. (b) One period xz slice of
PC shown in (a) including non-normal sidewall angles and mismatched duty
cycles that occur during fabrication.
and corresponding optical system to couple incident blue laser light to QDs for
multiplexed biomarker detection.
3.2 Device Structure
3.2.1 Photonic Crystals for Enhancement of Quantum Dots
Here, I describe the design and simulation of PCs that enhance the excitation
of QDs. These QDs are designed output uniform intensity light when excited
under the same conditions, even at different emission wavelengths [86]. Since
our collaborators in the Smith group plan to use multiple types of QDs for
multiplexed detection, PCs can only be designed to enhance QD excitation,
not emission. As mentioned previously, this is sufficient to enhance QD output.
The initial design was based off previous PCs designed for fluorophore
excitation at λ = 637 nm [7]. I began by scaling the parameters, shown in
Fig. 3.1a-b and described in Table 3.1, by the wavelength ratio between the





. After initial 2D simulations
using Rigorous Coupled Wave Analysis (RCWA) (DIFFRACTMOD, RSoft), I
iteratively optimized the parameters for maximum diffraction efficiency and
enhancement for TM plane-wave illumination at λ and φ as defined in Fig. 3.1a.
These results are shown in Fig. 3.2a-b. First, I optimized the slab (Si3N4)
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Table 3.1. Device parameters for PCs depicted in Fig. 3.1a-b.
Symbol Parameter Value
Λ Period [nm] 295
ts Si3N4 Thickness [nm] 112
tc SiO2 Thickness [nm] 0
h Grating Depth [nm] 28.1
fc Duty Cycle [%] 38.5
fs Si3N4 Fill Factor [%] 1.3× fc
θc SiO2 Side Wall Angle [°] 82
θs Si3N4 Side Wall Angle [°] 78
thickness, which changes the linewidth and position of the resonance. Next, I
adjusted the period, which shifts the resonance wavelength. Then I iteratively
optimized the duty cycle and the grating depth, both of which vary the
symmetry and linewidth of the resonance. For previous PC designs, the final
step was to optimize the cavity (SiO2) thickness, which shifts the Fabry-Perot
background in the cavity and changes the enhancement factor (on-resonance,
where λ, φ match the coupling conditions, vs. off-resonance, where λ, φ do not
match the coupling conditions). In those cases, the resonance peak should be
as close as possible to the Fabry-Perot minimum. However, in this case, the
Fabry-Perot background is minimized due to the use of a fused silica substrate,
as the refractive indices (RIs) of fused silica and SiO2 are almost identical.
Thus, for ease of fabrication, the cavity height is set to zero.
During these iterations, I used the diffraction efficiency vs. launch angle
(φ) simulation (Fig. 3.2b) to ensure that there is enough margin to achieve
resonance at some φ when the RI on the surface changes as the result of an
assay. The final design is a trade-off between maximum enhancement and
process capabilities. As an example, linewidth decreases, meaning Q-factor
increases, for decreased grating depth. However, etching only a small grating
depth, such as 15 nm, is difficult to reliably achieve. The linewidth at a grating
depth of 35 nm is not much larger, and diffraction efficiencies at depths of
35±10 nm are within 10%, providing a good compromise. The final electric field
simulations are shown in Fig. 3.3a-b for off- and on-resonance conditions. The
enhancement factor is ∼ 50× at 100 nm above the surface, which is comparable
to the previous PCs resonant at 637 nm.
PCs resonant at λ = 450 nm are being fabricated at Moxtek, a commercial
producer of optical polarizers and beamsplitters. The non-proprietary fabrica-
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(a) (b)
Fig. 3.2. Diffraction efficiency vs. (a) wavelength (φ = 0°) and (b) angle
(λ = 450 nm) for an ideal PC. Labels on the graph specify the resonance peaks.
tion details are as follows. For fabricating the 1D grating, a photoresist pattern
is transferred through an organic anti-reflective coating layer, which is first
used to make a thin (∼50 nm) Al hard mask. The Al mask is then used for
etching (via RIE) a 28.1 nm grating into the SiO2 cavity layer. Finally, the
Al is stripped off before Si3N4 deposition. Potential optimizations include a
thicker Al hard mask, with the lines trimmed to a lower duty cycle, in order to
achieve a 38.5% duty cycle in the final SiO2 grating.
3.2.2 Line Scanner Upgrade
A schematic of the upgraded detection instrument is shown in Fig. 3.4a-b. The
Cunningham group has previously published the system for detection of protein
(a) (b)
Fig. 3.3. (a) Off- and (b) on-resonance simulations of ideal PC. The
enhancement factor 100 nm above the surface is ∼ 50×.
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(a) (b)
Fig. 3.4. Upgraded line scanner model for (a) the red laser path and (b) the
blue laser path. The output beam is shown in purple.
and micro RNA cancer biomarkers [7]. Here, I have added an additional arm for
the blue laser (Fig. 3.4b) as well as upgraded and realigned all the components
to ensure proper focus and magnification. The illumination of this system
consists of two laser diodes. The red arm contains a 70 mW solid-state laser
(AlGaInP) at λ = 637 nm, while the blue arm contains an 80 mW solid-state
laser (InGaN) at λ = 450 nm. Before joining paths, each laser passes through a
half-wave plate in order to rotate its polarization perpendicular to the grating
on the PC surface. This ensures excitation is maximized. The dichroic mirror
at the intersection of the laser paths serves to reflect the λ = 450 nm laser at a
90° angle while transmitting the λ = 637 nm beam. Then, both beams pass
through a cylindrical lens (f = 150 mm), which focuses them onto the back
focal plane of an infinity-corrected 10× or 50× objective (Olympus Plan N)
such that a line is formed at the PC surface. A second dichroic mirror reflects
the laser excitation onto the PC surface while passing the longer wavelength QD-
emission onto the emission filter and tube lens (ftl = 200 mm) that projects the
fluorescence image onto the entrance slit of a Czerny-Turner spectrophotometer
(Horiba iHR550). At the exit of the iHR550 is an EMCCD camera (Hamamatsu
9100C). In imaging configuration, the iHR550 turret rotates to a mirror, while
in spectral configuration, the turret rotates to a 300 `/mm grating (600 nm
blaze wavelength). Using the 10× objective, the laser FWHM displayed on the
EMCCD is ∼6 µm.
The λ = 637 nm laser, half-wave plate, first dichroic mirror, and cylindrical
lens are placed on a motorized linear stepping stage (Zaber LSM-25), movement
of which results in a translation of the line focused laser on the back focal plane
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Table 3.2. PCEF system parameters used to calculate resolution limits.
Symbol Parameter Value
fobj Focal length of 10× objective [mm] 18
ftl Focal length of tube lens [mm] 200
wp Pixel width/height [µm] 16
Npixel Number of pixels in CCD (1D) 512
m Diffraction order 1
NA Numerical aperture of 50× objective 0.5
d Grating line spacing [µm/`] 3.33
ws Slit width [µm] 50
fspec Focal length of mirrors in Czerny-Turner setup [mm] 550
MCT Czerny-Turner magnification 1.1
of the objective, changing the incident angle in the φ direction. The PC is also
on a motorized sample stage (MS2000, Applied Scientific Instruments) which
translates in all 3 (x, y, z) directions to scan the sample surface (x, y) and to
focus the laser (z).
While not precisely a 10× magnification system,





the ftl = 200 mm is necessary to in order to have sufficient space between all
of the optical components.
3.2.3 System Resolution
Before taking experimental data, it is important to understand both spectral
and spatial resolution limits on imaging capability due to the components of
the PCEF system (parameters shown in Table 3.2). The spatial resolution is
simpler to calculate, as it does not depend on the slit width (ws) and grating
line spacing (d). There are two components to spatial resolution: spacing
limited by imaging wavelength and spacing resolved by the EMCCD. First, the









Thus, we cannot resolve features separated by less than 450 nm. Next, the
spatial resolution limited by the EMCCD (calculated here for the 50× objective),
which also determines the step size for scanning the laser line across the surface,













Note that, with a 50× objective, the camera can image smaller features than
can be resolved with visible light.
The spectral resolution of the system depends primarily on the characteristics
on the Czerny-Turner setup, which are also listed in Table 3.2. The linear
dispersion dl
dλ








where, for small θd, cos θd ≈ 1. Assuming the image of the slit on the CCD




















1 ∗ 550 mm
∗ 1.1 ∗ 50 µm = 0.333 nm
which means that the PCEF system can resolve spectral peaks that are at least
0.333 nm apart.
Both spatial and spectral information are combined on the EMCCD, as the
PCEF scanning system generates a spectrum for each point on the laser line.
There are thus different resolutions to consider in each of the final spectral
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(a) (b)
Fig. 3.5. Diffraction efficiency vs. (a) wavelength (φ = 0°) and (b) angle
(λ = 450 nm) for an ideal PC with an n = 1.4 biomarker on the surface
(r = 50 nm). Labels on the graph specify the resonance peaks.
images. The implications of this will be evident during the later discussion of
QD scans.
3.3 Results and Discussion
Simulated results are shown for two cases: a biomarker on the surface, similar
to detection during an assay, and imperfections that occur during fabrication.
I also show experimental results for QDs conjugated to single-stranded DNA
(ssDNA) on the PC surface.
3.3.1 Biomarker Simulation
Here, I used RCWA to simulate a biomarker as a sphere of radius r = 50 nm and
RI n = 1.4 on top of the PC grating, with the same 2D simulation conditions
specified previously (TM plane-wave illumination). Modeled reflection spectra
vs. wavelength and incident angle are shown in Fig. 3.5a-b. There is ∼0.3°
increase in the on-resonance angle from the original model with no biomarker.
This is similar to the incident angle shift that occurred in previous experiments
with one molecule, such as silane, on the surface. However, depending on the
surface treatment and assay conditions, there can be a much larger shift based
on how many layers of molecules are present on the surface. The PC is designed
so that the resonance angle increases with increased RI on the surface, and
31
(a) (b)
Fig. 3.6. Diffraction efficiency vs. (a) wavelength (φ = 0°) and (b) angle
(λ = 450 nm) for PC with non-normal sidewalls and non-uniform duty cycles.
Labels on the graph specify the resonance peaks.
there is sufficient margin in the detection system to accommodate incident
angles up to 12°.
3.3.2 Non-Ideal Structure Simulations
Here, I used RCWA to simulate non-perpendicular sidewall angles, as listed in
Table 3.1 and shown in Fig. 3.1b. Modeled reflection spectra vs. wavelength
and incident angle are shown in Fig. 3.6a-b. There is ∼0.6° increase in the
on-resonance angle, an increase in linewidth, and a decrease in diffraction
efficiency from the original model with normal sidewall angles. This is expected
given that the sidewalls introduce higher diffraction orders such that the light
can no longer be completely coupled into the structure. E2 field distributions
are shown for off- and on-resonance in Fig. 3.7a-b. The enhancement factor is
∼ 13× at 100 nm above the surface, which is similar to the actual performance
of the λ = 637 nm PCs.
3.3.3 Device Fabrication and Characterization
The devices were fabricated at Moxtek, a commercial company specializing
in wire-grid polarizers, as described previously. Due to the small duty cycle
and short grating height needed to maximize the resonance near λ = 450 nm,
fabrication required many iterations and design changes to produce a decent
yield. As shown in SEM images of Fig. 3.8a-b, there are both variations in
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(a) (b)
Fig. 3.7. (a) Off- and (b) on-resonance simulations of fabricated PC. The
enhancement factor 100 nm above the surface is ∼ 13×.
grating height and surface roughness that contribute to an increased linewidth
and lower quality factor than previous devices with a resonance peak near λ =
637 nm. With multiple design iterations, these inconsistencies were minimized
and the fabrication yielded a higher number of functional devices. The angle-
tuning ability of the PCEF system allows for a greater proportion of functional
devices, as a slightly shifted resonance peak can be tuned appropriately using
the instrument.
Figures 3.9a-b show measured PC spectra vs. wavelength and angle. To
measure power vs. wavelength, light transmitted through the PC from a white
light source (Ocean Optics DH-2000-BAL) is captured via a photodiode and
(a)
(b)
Fig. 3.8. (a) Cross-sectional




Fig. 3.9. (a) Transmission spectra and (b) peak reflected power angle
spectrum for fabricated PCs.
coupled via an optical fiber into a spectrometer (Ocean Optics USB2000). To
measure the reflected intensity vs. angle, I used the PCEF setup in Fig. 3.4b as
described in Section 2.2.2. Briefly, the angle of the light incident on the surface
is swept by translating a motorized stage, which focuses the laser at a different
point on the back focal plane of the objective. During this process, the software
captures images from the EMCCD camera at each step and computes the peak
reflected intensity. The PCEF setup is calibrated such that the on-resonant
angle corresponds to the wavelength dip found using the transmission setup.
3.3.4 Quantum Dot Fluorescence Scans
Before any testing, it is necessary to ensure that the surface of the PC is made
biocompatible by sputtering ∼10 nm of TiO2 on the Si3N4. In order to test
the enhancement properties of the new PCs resonant near λ = 450 nm, I used
commercially available QDs emitting at λ = 655 nm (Thermofisher Qdot™ 655
Streptavidin Conjugate). Streptavidin on the QD binds to biotin on one end
of the ssDNA (IDT 10mer DNA oligo), which is bound to the silanized (Sigma-
Aldrich (3-Glycidyloxypropyl)trimethoxysilane) surface of the PC via an amine
(Fig. 3.10). Absorption/emission spectra of QDs are shown in Fig. 3.11. Our
λ = 450 nm excitation laser is well within the range of excitation for the QDs,
as standard microscopes typically use a λ = 488 nm laser.
The first test was to validate QD enhancement. For this test, a high
concentration of QDs were dried on the surface. Using the method described
in Section 3.3.3, I found the angle at which peak reflection occurred for the
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Fig. 3.10. Surface chemistry of
QD-conjugated ssDNA on PC. Not to scale.
QD-coated PC (5.75°), completed a line scan (“on resonance”), and repeated
the procedure for normally incident light (“off resonance”). These results are
shown in Fig. 3.12, where the average enhancement factor is ∼ 5.5×. Note
that this enhancement is smaller than the predicted 13×. This is due to the
actual PC having an increased linewidth as a result of surface roughness and
other imperfections not accounted for in the simulated model.
After verification of enhancement, I performed line scans, using the system
described in Section 3.2.2, of the PC surface with different concentrations
of QDs bound to ssDNA. It is important to note that the surface is covered
with ssDNA, so the limiting factor is the concentration of QDs, as each QD
should bind to ∼1 ssDNA. The QD-streptavidin conjugates are only ∼20 nm
in diameter, thus they are diffraction-limited at visible wavelengths. As they
cannot be identified by size alone, single QDs are typically distinguished by
their characteristic blinking [107–109]. We did not see any such blinking while
observing QD output in real-time on the EMCCD camera, leading to the
conclusion that either the QDs are too highly concentrated to resolve or they
aggregated in solution. Future work is planned to explore these possibilities. We
verified that the emission was from QDs, rather than artifacts, using spectral
scans, discussed further in Section 5.2.2 and shown in Fig. 5.3a-c, that display







Fig. 3.12. (a) On resonance and (b) off resonance
scans of PCs coated with QD-conjugated ssDNA.
In Chapter 2, I performed scans of a dry surface, during which samples were
scanned upside down and light was reflected off of the PC surface back into
the objective (Fig. 3.4b). In this case, due to surface chemistry complications
drying the DNA/QD conjugate, I performed scans of the QDs in solution, right
side up, contained on the PC surface in ∼5 mm PDMS wells. As shown in
Fig. 3.13, there is enough margin in the PC design and the PCEF system to
accommodate the larger angle shift due to the increased RI on the surface of
the QD solution vs. air. It is important to note that, although extra QDs
are in solution, only the ones bound to DNA are visible because of the height
of the evanescent field on the PC. The QD aggregates are clearly visible in
Fig. 3.14a-c, but they are slightly more blurry than dry surfaces as a result of
the long working distance, low-NA objective directing the light through the PC
and back during each scan. Regardless of the blurriness of the image, it appears
that each 10× decrease in concentration correlates to ∼ 10× decrease in the
number of spots that can be physically counted on the surface. This leads to
high confidence in our system to both enhance QD emission and produce valid
results over a wide range of QD-labeled biomarker concentrations.
Fig. 3.13. Angle scans of PC inside
and outside of the PDMS well
containing QD solution. The surface of
the PC outside the wells is only




Fig. 3.14. QD normal incidence line scans at concentrations of (a) 1 nM,
(b) 100 pM, and (c) 10 pM.
3.4 Conclusion and Future Work
In this chapter, I showed simulations and experimental data of a new PC
to enhance 450 nm laser excitation for QDs and a redesigned optical system
to detect multiplexed QD emission. The electric field is up to 13× larger
at the PC resonance and the line scanner system can now be used to excite
both fluorophores (Cyanine-5) and QDs (at a variety of emission wavelengths
from 525 nm to 685 nm), as demonstrated experimentally using 655 nm QDs.
We plan to further investigate both the effects of using a low-NA objective
and the optimization of surface chemistry to more clearly image QDs on the
surface. We plan to use both the fluorescence imaging capability and the
spectral imaging capability of the PCEF system in order to detect multiplexed
QD-tagged ssDNA sequences. In future work, this system will be used to detect
QDs conjugated to messenger RNA variants to evaluate treatment efficacy in
metastatic castrate-resistant prostate cancer.
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CHAPTER 4




Photon emitters are the cornerstone of technologies that include medical diag-
nostics, video display, digital communication, and lighting. Classes of emitters
include phosphors, fluorescent chemical compounds, and semiconductor-based
quantum dots (QDs), which are each excited by an external illumination source
that stimulates emission at a specific wavelength. At the nanoscale, both
efficient coupling of excitation energy into the emitter and selective channeling
of its emission in a specific direction are key to obtaining optimal energy effi-
ciency, which in turn impacts achievable limits of detection for sensing disease
biomarkers, battery life of mobile devices, and power conversion efficiency of
lighting.
By incorporating photon emitters into custom-engineered nanostructures, it
is possible to substantially enhance the energy coupled into the nanostructures.
Photonic crystal (PC) nanostructures represent one example, as, under a specific
set of coupling conditions (a precise excitation wavelength and incident angle),
PCs sustain a resonant electromagnetic standing wave, with an evanescent
field extending beyond the surface that enhances the output of emitters within
that evanescent field. This results in up to 100× enhancement factor in
excitation power for emitters on the PC surface. However, PC-based resonant
energy enhancement has an important fundamental drawback: as the energy
enhancement factor increases, the resonant energy coupling condition becomes
more stringent, resulting in the need to precisely collimate and align the
excitation source.
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Fig. 4.1. Photoluminescence spectra
of a flake of the 2D semiconductor WS2
on the surface of a PHC, HMM, and Si
with native oxide reference substrate.
Reprinted with permission from [111].
©2016 American Chemical Society.
A novel class of materials allow us to achieve high enhancement factors for
photon emitters with far less stringent coupling conditions, resulting in energy
coupling to photon emitters that is not only highly efficient, but also rugged
enough for applications in which high mechanical stability and/or precise
optical alignments are not possible. Man-made optical metamaterials are being
explored for their unique properties in applications ranging from cloaking
devices to perfect lenses. These structures, typically fabricated by depositing
ultra-thin layers of alternating metals and dielectrics, allow engineering of
the interaction between light and matter that is not possible with naturally
occurring materials.
Metamaterials have been shown to provide unique field enhancement to
slot waveguides and to yield extra sensitivity for plasmonic biosensing de-
vices, supporting significant enhancement in metamaterial structures [71, 110].
Previously published reports have yet to fully explore the use of periodically
structured metamaterials for enhancement of photon emitters (such as QDs)
above the surface, as will be further explored and demonstrated here.
PCs using a metamaterial instead of a dielectric layer, called photonic hyper-
crystals (PHCs), have already been simulated in the infrared and microwave
regimes, where they can provide near-perfect, although lossy, lensing from light
at any incident angle, exhibiting an omnidirectional band gap [112]. They
have also been shown to enhance photoluminescence from 2D semiconductor
materials on the surface (Fig. 4.1) and have been made into perfect absorbers
[111, 113]. Here, I demonstrate that PHC structures are capable of resonant
electromagnetic coupling and enhancement over a large range of incident angles
for a laser illumination source. This results in efficient coupling with and high
enhancement of QDs for biosensing applications. My PHC design combines the
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Fig. 4.2. Anisotropic permittivities calculated for the Al-SiO2 HMM of
Fig. 4.3a (fill factor = 40%) using the effective medium approximation
(described in Section 4.2.3). <{εxy} < 0 while <{εz} > 0.
light engineering capabilities of PCs with the broadband enhancement effects
of metamaterials.
4.2 Device Structure
Hyperbolic metamaterials (HMMs) are fabricated by layering alternating metal
and dielectric materials [114]. They facilitate precise control of light propagation
as a result of the conductivity differences between the materials: electrons
flow freely across the metal surface, but not as easily between the layers,
resulting in different permittivities in different directions. For a selected
metal/dielectric combination, there are negative real permittivities (εr) in one
or more orientations of the crystal, while permittivities in the perpendicular
orientations remain positive, as shown in the example of Fig. 4.2. This is
the defining feature of an HMM. The unique physics of HMMs also permit
a wide variety of angles to couple into the structure, leading to broadband
enhancement effects. This will be further explored in Section 4.3.2.
HMMs are integral for the fabrication of PHCs, first described by Narimanov
in 2014 and shown in Fig. 4.3b-c [66]. A PHC consists of periodically structured
regions that contain metallic or dielectric materials layered with HMMs. Like
a PC, this periodicity can extend in 1-, 2-, or all 3-dimensions.
4.2.1 Simulations
I have fully designed and simulated a PHC structure using both commercially
available finite difference time domain (FDTD) electromagnetic computer sim-




Fig. 4.3. Schematic of HMM and PHC in air.
Red represents a metal material (Al), blue
represents a dielectric (SiO2), and green represents
the substrate (Si). Yellow circles represent emitters
and Ei is the incident field for (a) HMM,
(b) cross-sectional view of PHC with hexagonal
grating, and (c) unit cell of PHC on silicon
substrate.
layered structures (S4 [115]), exploring the effect of changing materials, device
structure, and layer thicknesses of the hexagonal PHC depicted in Fig. 4.3c.
Permittivity data for Al is from Brendel-Bormann model in Rakić et al., while
permittivity data for SiO2 is experimentally obtained by our previous collabo-
rators at Moxtek via ellipsometry [116]. Unless otherwise stated, simulations
are done in 3D and incident light is a TM-polarized plane wave at normal
incidence.
The combination of Al and SiO2 was chosen to optimize device performance
at 450 nm for compatibility with previous work detecting QDs (see Chapter 3).
I specifically used Al (as opposed to Ag or Au, which are also commonly used





, or the frequency at which the real part of the permittivity (εr)
crosses zero [117]. The ωp values for Ag and Au are too close to λ = 450 nm to
be able to form a metamaterial that extends sufficiently into the hyperbolic
range to yield large electromagnetic enhancements [118, 119]. SiO2 was chosen
for its relative ease of fabrication and its ability, in combination with Al, to yield
such a metamaterial based on the effective medium approximation described
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Table 4.1. Device parameters for PHC depicted in Fig. 4.3c.
Symbol Parameter Value
Λ Lattice constant [nm] 434
p Vertical period [nm] 30
ff Fill factor [%] 40
r Etch radius [nm] 123
tc SiO2 cap thickness [nm] 2
Np Number of vertical periods 8
Npetched Number of etched vertical periods 5
in Section 4.2.3. Other dielectrics, such as TiO2 or Al2O3, have too large a
permittivity or are too lossy at λ = 450 nm to be effective.
4.2.2 Optimization
Device optimization leads to a combination of an HMM (Al and SiO2) and
a dielectric (air) such that there exist broadband coupling conditions to the
PHC for improved enhancement of QDs. The design described here is based
on a structure by Galfsky et al. for a spontaneous emission enhancer and is
shown in Fig. 4.3c [111].
In order to optimize the device for λ = 450 nm at θ = φ = 0°, it is first
important to ascertain the physical effect of varying different parameters of
the PHC, which are shown in Table 4.1. The three most important factors in
optimization are the fill factor, lattice constant, and hole radius, as shown in
Fig. 4.4a-b. Before varying those, I set limits on the number of layers forming
the HMM, the number of etched layers in hole, and the layer thicknesses.
Theoretically, more layers of the HMM should yield a better performing device,
in terms of minimizing non-local effects from the vertical period p << λ
[120]. Practically, the amount of absorption in the metal does not yield
significantly increased performance (determined by simulations of reflected
power vs. wavelength) for the number of periods Np > 8. Similarly, the number
of etched layers yields maximum performance at Npetched = 5. Etching exactly
this distance during device fabrication will likely not be feasible, but it is
sufficient for optimization purposes. Finally, the value of p has no effect on
the device performance as long as it is significantly subwavelength. Here I set




Fig. 4.4. Optimizing peak enhancement at 50 nm above the surface for the
parameters of the PHC (a) fill factor and (b) hole radius and lattice constant.
After the relatively straightforward task of optimizing the HMM, I used S4
to iterate through all combinations of fill factor (ff), lattice constant (Λ) and
hole radius (r) to achieve the peak E2 at z = 50 nm above the PHC surface.
The height z = 50 nm was chosen because that is approximately the distance
of the QD-conjugated single-stranded DNAs above the silanized surface for the
experiments described in Chapter 3. The combination of Λ and r determine the
wavelength at which the maximum enhancement occurs, as shown in Fig. 4.4b.
The optimal r ∝ Λ, but varying Λ has the larger effect. For optimizing the
device for λ slightly greater (less) than 450 nm, given that all other factors
remain the same, all that is needed is to increase (decrease) Λ while keeping
r/Λ constant. Finally, varying ff (Fig. 4.4a) increases or decreases the value
of E2, but does not spectrally shift the peak E2.
4.2.3 Effective Medium Response
Although I used computational methods to simulate the full response of the
HMM, the effective medium approximation (EMA) allows for averaging the
periodic layers into a metasurface with one effective permittivity εeff. The EMA
















And, finally, the EMA for the metal (ε1)/dielectric (ε2) structure with









z = f1ε1 + f2ε2
The EMA is not sufficient for periodic layers with lossy materials due to
abnormal field fluctuations between the layers. Thus, a more rigorous EMA
with non-local corrections is needed to account for the variations introduced
by plasmonic materials [121, 122]. Although I did not use such calculations
here, it is important to understand the implications of non-local corrections
in the design of HMMs and PHCs. Briefly, for low-order modes, plasmonic
materials do not induce large variations in ε and can be approximated with the
non-local corrections below. The need for these approximations decreases with
increasing number of layers. Higher order modes in an HMM can be localized
in areas as small as λ/8, reducing the accuracy of the non-local correction
approximations, as these variations do not occur in all-dielectric or in larger












































where the choice of kx = 2πj/h instead of kz or ky for the j
th mode and h = Npp
is somewhat arbitrary.
4.2.4 Fabrication Plan
The most difficult part of the fabrication process would be optimizing deposition
in one chamber that can handle both Al and SiO2, as removing the sample
from vacuum between deposition layers will introduce oxidation of the Al layer.
Previously published PHCs were fabricated by sputtering Ag and Al2O3 in
the same chamber, with a thin seed layer of Ge before Ag to facilitate layer
smoothness [111, 123]. Sputter deposition of Al introduces similar challenges
without the addition of a thin metal (∼1 nm to 2 nm) layer, such as Ti [124, 125].
Thus, the initial fabrication plan is to optimize sputter deposition of the
materials to form thin layers in the repeating order SiO2-Ti-Al.
After any deposition, it is important to note that the interface between Al
and SiO2 will not be pure due to the room-temperature reaction between the
materials [126]. Once equilibrated to room temperature, it is thermodynami-
cally favorable for O2 at the interface to bind to Al instead of SiO2, forming
an Al-Al2O3-Si-SiO2 structure. This effect does not occur in vacuum during
the deposition process. However, the total thickness of this interface is no
more than 1 nm to 2 nm, meaning that there is no need for an interface layer
to mitigate negative effects of the oxidation-reduction reaction, as the interface
layer would be just as thick [127, 128].
A wide variety of etchants and lithography tools are available to fabricate
holes in the metamaterial structure [129]. Here, I propose focused ion beam
milling as the final step in the PHC creation in order to etch holes on the
surface [111]. While time consuming, it has an advantage over traditional
etchants because of the multiple materials involved and because of the small
feature sizes.
4.3 Results and Discussion
Here I show the polarization independent response of simulating (via S4 and
FDTD) the PHC in Fig. 4.3c and Table 4.1, as described in the previous sections.
This polarization independence is due to the hexagonal lattice symmetry of
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the crystal. Using this PHC for biosensing, instead of the PC described in
Chapter 3, means that increased laser power would be transmitted to the
surface, not having been lost to the half wave plate or the polarizer. This allows
the use of less complex optical setups and ensures that the laser has more
than sufficient power. The PHC also does not require as stringent coupling
conditions as the PC, so QD-conjugated biomarkers can be detected using a
standard microscope.
4.3.1 PHC Response
The Cunningham group’s current PCs require a cylindrical lens to focus light
to a line, along with a method of adjusting the incident angle of the line on
the surface. This is because a slight refractive index shift on the surface (due
to the presence of the biomaterials) changes the coupling conditions, or the
wavelength and angle at which maximum enhancement is achieved. Using the
PHC, enhancement is slightly reduced in favor of increased bandwidth. This
results in less stringent coupling conditions, yielding consistent enhancement
at normal incidence that is relatively independent of refractive index shifts due
to surface density changes or other biomaterial variations.
Figures 4.5a-b demonstrate the relatively broadband operation of the PHC.
Reflected power is minimized at λ = 450 nm (Fig. 4.5a), while the θ response
is unchanged for φ < 10° (Fig. 4.5b). In Fig. 4.6a-b, both average and peak E2
at the surface are maximized at λ = 450 nm, independent of polarization, as
expected.
Cross-sections of the electromagnetic enhancement reveal what look anal-
ogous to modes (in traditional PCs) in the holes. At normal incidence
(Fig. 4.7a/c), there is strong enhancement near the edges, with minimal en-
hancement in the center of the ridges. For QDs (or other reporters) sitting in
or near the edges of the holes, > 10× average enhancement above the surface
is predicted. This enhancement occurs for a wider band of angles than was
possible with the previous generation of PCs. For off-angle response, the peak
enhancement is slightly higher, but the field is not uniform and the average
enhancement above the surface decreases as shown in Fig. 4.7b/d.
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(a) (b)
Fig. 4.5. Reflected power vs. (a) wavelength and (b) incident angle (φ/θ) for
PHC.
4.3.2 Response of PC vs. PHC
As mentioned previously, PCs have a very large enhancement factor, but only
for very stringent coupling conditions. The PHC has more uniform, although
smaller, enhancement that is spread over a wider band of angles, reducing the
need for custom equipment and specialized optics. This is demonstrated in
Fig. 4.8a-b. Enhancements for the PC are ∼ 30× larger than for the PHC, but
the PHC yields enhancement over 100× for |φ| < 10° rather than the φ ≈ 0.3°
range of the PC.
The wide bandwidth of the PHC is further exemplified in the band diagram of
Fig. 4.9b. The stringent coupling conditions (shown by peak reflected power) of
the PC are, again, in stark contrast to the wide band (shown by peak absorbed
(a) (b)
Fig. 4.6. (a) Average and (b) peak enhancement (at z = 0 nm) vs.




Fig. 4.7. Cross-sections of E2 values in PHC for λ = 450 nm and θ = 0° at
(a)/(c) maximum enhancement (φ = 0°) and (b)/(d) φ = 10°. (a) and (b) are
at y = 0, while (c) and (d) are at z = 0 and represent the response of
unpolarized light. High enhancement always occurs within and near the edges
the hole regions.
power) of the PHC. Any change in the refractive index on the PC surface will
require an adjustment in angle to match the new coupling conditions, while




Fig. 4.8. Comparison of peak E2 curves for a (a) PC resonant near
λ = 450 nm and (b) a PHC designed to maximize enhancement at λ = 450 nm.
4.3.3 Biomarker Response
I have simulated (via FDTD) a biomarker as a sphere of radius r = 50 nm
and RI n = 1.5. As shown in Fig. 4.10a-b, enhancement increases near the
biomarker due to its interaction with the PHC. This means high enhancement
at normal incidence is still achievable, even when materials with different
refractive index are present on the PHC surface. For dielectric 1D photonic
crystals, the presence of biomaterial on the surface requires angle tuning to
achieve significant enhancement.
(a) (b)
Fig. 4.9. Simulated band diagrams for (a) PC and (b) PHC. Yellow indicates
high reflectivity, blue indicates low reflectivity. Note that enhancement is
maximized in the PC at peak reflected power, and enhancement is maximized




Fig. 4.10. Simulated PHC when r = 50 nm, n = 1.5 biomarker is located
(a) in the hole and (b) on top of the ridge.
It is important to note that a uniform 50 nm layer of biomaterial on the PHC
surface would not yield significant enhancement, but such is not the result of
surface preparation. There would be a ∼10 nm layer of silane, and actual bound
biomarkers are not nearly as densely packed. If surface preparation significantly
red-shifts the enhancement, it would be fairly simple to redesign the PHC with
margin to account for the standard chemistries used. The 50 nm sphere was
chosen to highlight the area in which a biomarker might be located to estimate
the enhancement factor of a QD bound near the edge. This enhancement is
significantly higher in the well (> 20×) vs. outside of the well (∼ 7×), as
would be expected from the enhancement profiles in Fig. 4.7a. Given that the
holes cover ∼ 30% of the PHC surface area, this yields an average enhancement
factor of ∼ 12×.
4.4 Conclusion and Future Work
I have designed and simulated a novel optical metamaterial configuration of
a PHC that is capable of enhancing QD emission for biosensing applications.
While a conventional PC has > 30× larger enhancement, a PHC facilitates
enhancement over a much broader range of angles (|φ| < 10°). The PHC
averages ∼ 15× enhancement and peaks at > 100× enhancement at the surface.
During the design process, I optimized and ascertained the physical effects of
varying PHC parameters, leading to a repeatable process for producing future
PHCs. Especially important for portable, low-cost healthcare applications is
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the design of the PHC at λ = 450 nm where I believe its unique enhancement of
QD-tagged biomarkers will have an especially meaningful impact. Future work
will involve fabricating and characterizing this PHC followed by experimentally










There exist a variety of treatment options for metastatic castrate-resistant
prostate cancer (mCRPC), including targeted therapies [130–133], vaccines
[134], chemotherapies [135], and other drugs. Given all of these options, with
the prospect of many more [136], it is difficult to find the optimal drug therapy
[130, 131]. Even tracking disease progression to determine whether a drug
therapy is optimal is difficult for two main reasons: first, there are few uniform
standards for evaluating patient progress; second, the therapy needs to be given
enough time to be effective, as a tumor may initially grow before it begins to
shrink [137, 138].
A new candidate for monitoring disease progression is androgen receptor
variant (AR-V) expression in blood [139, 140]. The AR gene controls androgen
signaling in prostate cells and consists of two main sections: an N-terminal
domain and a variable domain. An AR-V differs from a full-length AR (AR-
FL) in the variable domain. Certain AR-Vs have been shown to promote
tumor progression and serve as biomarkers for monitoring therapies [141–144].
However, reliably detecting AR-Vs in blood has proven to be difficult, as
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concentrations are in the attomolar (10−18 M) range, which requires single
molecule sensitivity [145, 146].
In order to detect the AR-Vs, we propose using a modified version of
fluorescence in situ hybridization (FISH) that is widely used to detect single-
stranded DNA (ssDNA) and messenger RNA (mRNA) in tissue samples [147],
as shown in Fig. 5.1a-b. Standard FISH has high enough sensitivity and
specificity such that it can detect single molecules, with the technique being both
reproducible and inexpensive. The three main steps to performing FISH are:
first, fluorescently-tagged nucleic acid probes bind to complementary sequences
of ssDNA or mRNA in sample; second, the signal is amplified with multiple
fluorescently-tagged nucleic acid binding events; third, the sample is imaged
using standard fluorescence microscopy. Traditional mRNA amplification (such
as qRT-PCR) uses only a single nucleic acid binding event, but FISH uses
20-50 dyes on a strand with much higher sequence specificity and which emits
a clearer signal, as shown in Fig. 5.2.
In order to quickly and reliably detect AR-Vs in blood, we will implement
three improvements to FISH: first, our collaborators in the Smith group will
tag mRNA with multiple colors using quantum dots (QDs) to detect both
the AR-FLs and the AR-Vs, each with different sequences (Fig. 5.1b); second,
we plan to use microfluidics to improve assay time and standardize work flow
[79, 149]; finally, I plan to use a new photonic crystal (PC) and line-scanning
detection instrument (both described in Chapter 3) for signal amplification
and imaging. The ultimate goal is to have an automated, multiplexed method
for the detection of single-molecules in blood. All that would be needed for
the test is ∼10 µL of plasma, which is contained in just a few drops of blood
from a finger-prick.
5.1.2 Significance
FISH is a proven, simple, low-cost mRNA sequence detection methodology
that we plan to modify in order to detect AR-Vs, a biomarker for mCRPC, in
a few droplets of blood. It is currently difficult to detect single molecules in
blood using more traditional methods like qRT-PCR and mRNA sequencing,
but FISH, typically used in tissue biopsy samples, will improve upon on that.




Fig. 5.1. (a) Depiction of N-terminal domain (yellow, E1) and variable
domain (green, red, and blue) sequences for the AR-FL and AR-Vs. Adapted
by permission from Springer Nature: [148], ©2011. (b) Modified FISH
protocol utilizing QD tags for a liquid biopsy. The AR-V strands are held to
the surface by capture probes, and multi-colored QDs are attached via ssDNA
probes for imaging.
establishing the efficacy of a drug treatment regimen. Current methods for
monitoring disease progression are yet not specific enough to be tailored to
each patients unique biology. Thus, we hope to improve outcomes and reduce
treatment time for mCRPC patients.
5.1.3 Competing Approaches
Comparable DNA-based methods, including qRT-PCR, digital PCR (dPCR),
and RNA sequencing, are either not sensitive enough or are too expensive. In
particular, qRT-PCR only has femtomolar (10−15 M) sensitivity, 1000× less
than what is needed for single-molecule detection [151]. dPCR is a relatively
new technology. While being more precise than qRT-PCR, it has comparable
sensitivity and requires more expensive equipment and more expertise [152, 153].
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Fig. 5.2. (a) β- (green) γ- (red) actin mRNA in the cytoplasm of a cell.
(b) Individual β- and γ-actin mRNA molecules. (c) The detection of
cis-sequences in β-actin mRNA. (d) Intramolecular measurement in β-actin
mRNA. Single-molecules are resolved with digital imaging and deconvolution
techniques. From [150]. Reprinted with permission from AAAS.
Finally, RNA sequencing is still too expensive to justify repeated testing during
drug therapy [137].
Different treatments produce different responses at different rates in different
people, which makes the efficacy of any therapy nearly impossible to ascertain
[137]. An example of this treatment/response unpredictability is the prostate-
specific antigen (PSA) level. Even in an effective therapy, levels of PSA can
rise before they begin to fall, making it a non-uniform indicator for treatment
efficacy [137]. Another example of this unpredictability is imaging methods,
including X-ray, CT scan, bone scan, and MRI, which can reveal mCRPC
tumors in various organs and/or lymph nodes. These tumors not only take
time to appear in scans, but they can also be too small to discern [137]. In
bone scans, it is especially difficult to detect changes in bone metastasis size
or intensity between scans, which are both indicators of mCRPC progression.
Again, metastases in bone scans can appear to get larger before they shrink
[137]. None of these options are reliable indicators on their own, and even




In order more effectively perform the modified FISH assay, we plan to use
a microfluidic system to both automate and expedite the assay process, to
tag nucleic acid sequences in AR-Vs with multiple differently colored QDs,
and to design custom PCs to amplify QD output for single-molecule detection.
These three steps will enable a reduction in the amount of time and equipment
needed for performing the assay, enabling point-of-care detection. This unique
combination of chemistry, microfluidics, and engineering will allow the reliable,
inexpensive detection outside of the traditional lab environment.
PCs for enhancing multicolor QD-tagged ARs
The Cunningham group has previously designed PCs to enhance QD emis-
sion [100–103]. However, these all reported enhanced QD output at a single
emission wavelength. The Cunningham group has also previously shown that
enhancing QD excitation alone will enhance the emission [103], but this is, to
our knowledge, the first effort to use one PC surface to enhance the output of
multiple colors of QDs.
QDs have previously been used in FISH [154, 155], but nobody to our
knowledge has amplified either QD or fluorescent dye emission to make the
method more sensitive. FISH already has single-molecule sensitivity, so the
goal is that QD-coupled PCs will increase the visibility and robustness of the
assay.
Spectroscopic line scanner and analysis
As the line scanner is unique to the enhancement of the Cunningham group PCs,
any improvements made it are novel. The innovation here is the combination
of custom hardware and software with the goal of automated assay analysis,
from performing the PC surface scans to analyzing the resulting spectra and
reporting a count of AR-Vs. We are working toward the development of an




I have designed a PC resonant near λ = 450 nm and built a line scanning
instrument to enhance and detect the QD output as described in Chapter 3.
Briefly, QDs are semiconductor nanoparticles that can be tuned to emit visible
light at intensity up to 1000× that of fluorescent dyes [156]. They can be
attached to nucleic acids that bind with mRNA for FISH [157], and their
resistance to photobleaching, broad excitation spectra, and high quantum-yield
make them ideal for generating stable, robust signals [92]. The PCs are designed
to enhance excitation of the QDs, as the emission wavelengths in the visible
regime range from 525 nm to 685 nm. Enhanced excitation should also increase
the emission of the QDs while facilitating the performance of FISH assays with
multiplexed detection of AR-Vs [103].
5.2.1 PCEF System Validation
The design and fabrication of these PCs was thoroughly described in Chapter 3.
Briefly, I have designed a new PC for excitation with a 450 nm laser to overlap
with QD excitation. It is fabricated with a 28.1 nm SiO2 grating (Λ = 295 nm,
fc = 38.5%) on a fused silica substrate. This is overcoated with a 112 nm
thick Si3N4 layer. Each wafer is then diced into 12 mm× 25 mm pieces for
performing assays.
Around 100 nm above the surface, the PC has an ideal enhancement factor of
∼ 50×. Accounting for variations during fabrication, I expect an enhancement
factor of ∼ 10− 15×. Based on experimental work, I expect a resonance angle
shift of 5° to 8° to couple the 450 nm laser to the surface functionalized with
QD-tagged AR-Vs.
Given that preliminary validation of QD enhancement was completed in
Chapter 3, the task here will be to validate enhancement of QD-tagged AR-Vs
on a PC surface. However, supplies of patient AR-Vs are limited, so we plan to
do this with commercially available, custom mRNA sequences. The first step
is to work with our collaborators to get the surface chemistry correct such that
mRNA are immobilized and dried on the PC surface. Current members of the
Cunningham lab have performed this successfully and are working to adapt
the technique for this project. One area we are actively exploring is how to
dry the biomarkers on the PC surface, given that imaging them in solution is
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non-ideal with the low-NA lens in the current PCEF setup. Future integration
with the microfluidic chip will eliminate this issue (see Chapter 2).
The second step is to validate enhancement of QDs with varying emission
wavelengths. This will first be performed with mRNAs that are only tagged
with one QD type at a time. Once we measure enhancement factor profiles
and emission intensities for all QDs separately, then we can start investigating
performance of the PC with multicolored QDs.
Finally, both the scanning and analysis software were improved significantly
for speed and ease of use in Chapter 2. Preliminary validation of line scanner
results and images was performed as a part of the work in Chapter 3. However,
once we get multicolored mRNAs, we need to validate the spectral results
against known locations and transcription sequences (via color) of the mRNAs.
Spectral line scanning is already functional (Fig. 5.3a-c), but we need to
optimize the EMCCD camera settings after finalizing the assay protocol. Then,
we will validate location finding and color calibration with known mRNA
samples in an assay on the PC surface. This will be done in conjunction with
validation of the QD enhancement as described previously.
5.2.2 Spectral Image Collection and Analysis
The redesign of the line scanning detection system was also thoroughly described
in Chapter 3. Briefly, the Cunningham group has the capability to use both
red (λ = 637 nm) and blue (λ = 450 nm) laser light for excitation of fluorescent
dyes or QDs. The PCEF system is a customized microscope that focuses light
to a line, rather than a point, on the functionalized surface to couple light into
the PC using one precise angle. This line is then focused on the entrance slit of
a Czerny-Turner spectrophotometer, which can be in either spectral or imaging
mode depending on whether the turret is rotated to a 300 `/mm grating or a
mirror.
I propose using the line scanner in spectrometer mode to obtain the spectrum
of each location on the PC. This will require custom software to analyze this
spectral data to both map multiplexed QD emissions to their respective regions
on the PC and to match these to corresponding mRNAs (and, later, AR-Vs).




Fig. 5.3. Spatial reconstruction of
spectral line scans. (a) Single frame of
spectral line scan (y ≈ 2.6 µm), where the
x−axis is the spectral direction and the
y−axis is the laser line. Two QDs can be
seen by their spectral center ∼655 nm.
(b) By collapsing all QD spectra found in
(a) into one dimension, each line is stacked
to form the spatial image. (c) Fluorescence
scan for comparison to spectral
reconstruction of (b). Bright spots are
aggregate artifacts.
data. The aggregate data should then enable the reporting of a count of each
type of detected AR-V for interpretation by an oncologist.
5.3 Conclusion and Future Work
In this chapter, I have proposed a new method of monitoring treatment for
mCRPC, taking advantage of PC and QD technology that exists at the Uni-
versity of Illinois. We plan to use PCs and QDs to multiplex and amplify
detection of AR-Vs, a biomarker for mCRPC, at the single-molecule sensitivity
level. The goal is to make this a low-cost, portable instrument for point-of-care
detection that can be expanded to other diseases with different biomarkers.
Much of the work here is built off previous papers and has been preliminarily
completed as described in Chapter 3. The main objective is to integrate
enhancement of multiplexed QDs conjugated to mRNA and, eventually, AR-Vs
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using the newly designed PC and upgraded line scanner. We are currently in
the process of exploring the assay protocol to achieve dried QD-conjugated
ssDNA bound to the PC surface. This improves resolution and collection
efficiency because light from the QDs cannot scatter in solution or through the
PC while traveling to the objective.
The largest complication I anticipate is the potential for variable amplification
of the QDs bound to the AR-Vs. Previous work has only used amplification
of one layer of fluorophores ∼200 nm above the PC surface. In this proposal,
there will be QDs extending the length of the AR-V from ∼50 nm to a few
hundred nanometers, depending on the conformation of the DNA. There is
significant enhancement at 50 nm but no enhancement beyond ∼200 nm. This
could present a complication both when trying to count QDs, as they will not
be of uniform intensity, and when trying to enhance emission of the QDs. I
plan to fully characterize enhancement in the vertical direction and potentially





In this work, I have described a photonic crystal and line scanning detec-
tion/analysis system to aid in the screening and treatment monitoring of two
types of cancer: oropharyngeal cancer (OPC) and metastatic castrate-resistant
prostate cancer (mCRPC). I first developed an automated protocol for instru-
mentation used to improve screening for OPC, which can also be used for future
disease biomarkers. I also detailed the design and testing of a new system
that will be used to image quantum dot-tagged messenger RNA variants as a
disease progression marker for mCRPC. Finally, I introduced a design using
hyperbolic metamaterials in photonic crystals, forming photonic hypercrystals,
to improve control over light-matter interaction.
All of these developments progress toward the ultimate goal of a portable,
low-cost detection system to advance the screening for and tracking of diseases,
including, but not limited to, cancer. More specifically, I have improved
automation of the spot detection and data analysis, reducing error-prone manual
work and decreasing the time to results. I also improved the utility of the
detection system by facilitating the use of quantum dots instead of fluorophores,
improving brightness and decreasing photobleaching for applications requiring
high sensitivity. Finally, by exploring metamaterials, I expanded the utility
of photonic hypercrystals for biosensing. These new materials offer unusual
physics not possible in dielectrics and provide the flexibility for further design
customizations and device improvements.
All of these technologies will improve future work on photonic crystal en-
hanced fluorescence (and quantum dots) by both expanding disease screening
capabilities and simplifying optical detection setups. They will also allow the
next generation of researchers to use advances in inexpensive CMOS cameras
and 3D printing technology to make affordable screening devices available
outside of traditional lab settings, making healthcare more accessible.
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